REVIEW ARTICLE |
|
Year : 2022 | Volume
: 23
| Issue : 1 | Page : 1-9 |
|
Transcatheter aortic valve implantation for degenerated surgical aortic bioprosthesis: A systematic review
Abdallah El Sabbagh1, Mohammed Al-Hijji2, Mayra Guerrero3
1 Department of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida, USA 2 Department of Adult Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar 3 Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
Correspondence Address:
Dr. Mayra Guerrero Department of Cardiovascular Diseases, Mayo Clinic, 200 First St Sw, Rochester, Minnesota 55905 USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/heartviews.heartviews_25_22
|
|
Background: Transcatheter aortic valve in valve (Aviv) replacement has been shown to be an effective therapeutic option in patients with failed aortic bioprosthetic valves. This review intended to evaluate contemporary 1-year outcomes of Aviv in recent studies. Methods: A systematic review on outcomes of Aviv was performed using the best available evidence from studies obtained using a MEDLINE, Cochrane database, and SCOPUS search. Endpoints of interest were survival, coronary artery obstruction, prosthesis-patient mismatch (PPM), stroke, pacemaker implantation, and structural valve deterioration. Results: A total of 3339 patients from 23 studies were included. Mean age was 68–80 years, 20%–50% were female, and Society of Thoracic Surgeons score ranged from 5.7 to 31.1. Thirty-day all-cause mortality ranged from 2% to 8%, and 1-year all-cause mortality ranged from 8% to 33%. Coronary artery obstruction risk after Aviv ranged from 0.6% to 4%. One-year stroke ranged from 2% to 8%. Moderate-severe PPM occurred in 11%–58%, and pacemaker rate at 1 year ranged from 5% to 12%. Conclusion: Transcatheter aortic ViV has emerged as an effective therapeutic option to treat patients with failed bioprostheses. The acceptable complication rate and favorable 1-year outcomes make Aviv an appropriate alternative to redo surgical aortic valve replacement.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|